nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—VEGFA—sarcoma	0.409	1	CbGaD
Carvedilol—XDH—Doxorubicin—sarcoma	0.043	0.158	CbGbCtD
Carvedilol—CYP1A1—Dacarbazine—sarcoma	0.0375	0.138	CbGbCtD
Carvedilol—CYP2E1—Dacarbazine—sarcoma	0.029	0.106	CbGbCtD
Carvedilol—CYP2E1—Mitoxantrone—sarcoma	0.0225	0.0825	CbGbCtD
Carvedilol—PTGS1—Etoposide—sarcoma	0.0184	0.0673	CbGbCtD
Carvedilol—CYP1A2—Dacarbazine—sarcoma	0.0168	0.0615	CbGbCtD
Carvedilol—CYP3A4—Thiotepa—sarcoma	0.0159	0.0581	CbGbCtD
Carvedilol—CYP2E1—Etoposide—sarcoma	0.0142	0.052	CbGbCtD
Carvedilol—ABCB1—Dactinomycin—sarcoma	0.0127	0.0466	CbGbCtD
Carvedilol—ABCB1—Mitoxantrone—sarcoma	0.0114	0.0417	CbGbCtD
Carvedilol—NPPB—pulmonary artery—sarcoma	0.00854	0.0942	CbGeAlD
Carvedilol—CYP1A2—Etoposide—sarcoma	0.00821	0.0301	CbGbCtD
Carvedilol—ABCB1—Vincristine—sarcoma	0.00783	0.0287	CbGbCtD
Carvedilol—ABCB1—Etoposide—sarcoma	0.00718	0.0263	CbGbCtD
Carvedilol—CYP3A4—Mitoxantrone—sarcoma	0.00682	0.025	CbGbCtD
Carvedilol—ABCB1—Doxorubicin—sarcoma	0.00489	0.0179	CbGbCtD
Carvedilol—CYP3A4—Vincristine—sarcoma	0.00469	0.0172	CbGbCtD
Carvedilol—CYP2D6—Doxorubicin—sarcoma	0.00461	0.0169	CbGbCtD
Carvedilol—CYP3A4—Etoposide—sarcoma	0.0043	0.0158	CbGbCtD
Carvedilol—GJA1—periosteum—sarcoma	0.00421	0.0464	CbGeAlD
Carvedilol—SELE—umbilical vein—sarcoma	0.00381	0.042	CbGeAlD
Carvedilol—VCAM1—umbilical vein—sarcoma	0.00351	0.0387	CbGeAlD
Carvedilol—CYP3A4—Doxorubicin—sarcoma	0.00293	0.0108	CbGbCtD
Carvedilol—GJA1—Vinorelbine—Vincristine—sarcoma	0.00202	1	CbGdCrCtD
Carvedilol—SELE—endothelium—sarcoma	0.00181	0.0199	CbGeAlD
Carvedilol—VCAM1—endothelium—sarcoma	0.00166	0.0183	CbGeAlD
Carvedilol—HIF1A—endothelium—sarcoma	0.0016	0.0176	CbGeAlD
Carvedilol—GJA1—endothelium—sarcoma	0.00155	0.0171	CbGeAlD
Carvedilol—NPPB—myometrium—sarcoma	0.00153	0.0169	CbGeAlD
Carvedilol—SELE—mammary gland—sarcoma	0.00146	0.0161	CbGeAlD
Carvedilol—NPPB—hematopoietic system—sarcoma	0.00131	0.0145	CbGeAlD
Carvedilol—NPPB—smooth muscle tissue—sarcoma	0.00116	0.0128	CbGeAlD
Carvedilol—NDUFC2—mammary gland—sarcoma	0.00109	0.012	CbGeAlD
Carvedilol—SELE—myometrium—sarcoma	0.00103	0.0114	CbGeAlD
Carvedilol—NPPB—cardiac atrium—sarcoma	0.000998	0.011	CbGeAlD
Carvedilol—VCAM1—myometrium—sarcoma	0.000951	0.0105	CbGeAlD
Carvedilol—SELE—seminal vesicle—sarcoma	0.000934	0.0103	CbGeAlD
Carvedilol—NPPB—lymphoid tissue—sarcoma	0.000925	0.0102	CbGeAlD
Carvedilol—HIF1A—myometrium—sarcoma	0.000915	0.0101	CbGeAlD
Carvedilol—SELE—hematopoietic system—sarcoma	0.000887	0.00978	CbGeAlD
Carvedilol—GJA1—myometrium—sarcoma	0.000887	0.00978	CbGeAlD
Carvedilol—HIF1A—embryo—sarcoma	0.00088	0.0097	CbGeAlD
Carvedilol—VCAM1—seminal vesicle—sarcoma	0.000859	0.00947	CbGeAlD
Carvedilol—SELE—connective tissue—sarcoma	0.000854	0.00942	CbGeAlD
Carvedilol—GJA1—embryo—sarcoma	0.000853	0.00941	CbGeAlD
Carvedilol—HIF1A—seminal vesicle—sarcoma	0.000826	0.00911	CbGeAlD
Carvedilol—VCAM1—hematopoietic system—sarcoma	0.000816	0.009	CbGeAlD
Carvedilol—GJA1—seminal vesicle—sarcoma	0.000802	0.00884	CbGeAlD
Carvedilol—VCAM1—connective tissue—sarcoma	0.000786	0.00867	CbGeAlD
Carvedilol—HIF1A—hematopoietic system—sarcoma	0.000785	0.00866	CbGeAlD
Carvedilol—SELE—smooth muscle tissue—sarcoma	0.000782	0.00862	CbGeAlD
Carvedilol—NDUFC2—myometrium—sarcoma	0.000772	0.00852	CbGeAlD
Carvedilol—SELE—skin of body—sarcoma	0.000772	0.00851	CbGeAlD
Carvedilol—GJA1—hematopoietic system—sarcoma	0.000762	0.0084	CbGeAlD
Carvedilol—HIF1A—connective tissue—sarcoma	0.000756	0.00834	CbGeAlD
Carvedilol—GJA1—connective tissue—sarcoma	0.000734	0.00809	CbGeAlD
Carvedilol—VCAM1—smooth muscle tissue—sarcoma	0.000719	0.00793	CbGeAlD
Carvedilol—VEGFA—myometrium—sarcoma	0.000701	0.00772	CbGeAlD
Carvedilol—NDUFC2—seminal vesicle—sarcoma	0.000698	0.00769	CbGeAlD
Carvedilol—HIF1A—smooth muscle tissue—sarcoma	0.000692	0.00763	CbGeAlD
Carvedilol—HIF1A—skin of body—sarcoma	0.000683	0.00753	CbGeAlD
Carvedilol—ADRB3—connective tissue—sarcoma	0.000672	0.00741	CbGeAlD
Carvedilol—GJA1—smooth muscle tissue—sarcoma	0.000671	0.0074	CbGeAlD
Carvedilol—SELE—uterus—sarcoma	0.00067	0.00739	CbGeAlD
Carvedilol—NDUFC2—hematopoietic system—sarcoma	0.000663	0.00731	CbGeAlD
Carvedilol—GJA1—skin of body—sarcoma	0.000662	0.0073	CbGeAlD
Carvedilol—SELE—lymphoid tissue—sarcoma	0.000625	0.00689	CbGeAlD
Carvedilol—VCAM1—cardiac atrium—sarcoma	0.00062	0.00683	CbGeAlD
Carvedilol—VCAM1—uterus—sarcoma	0.000617	0.0068	CbGeAlD
Carvedilol—HIF1A—cardiac atrium—sarcoma	0.000596	0.00658	CbGeAlD
Carvedilol—HIF1A—uterus—sarcoma	0.000593	0.00654	CbGeAlD
Carvedilol—SELE—tendon—sarcoma	0.000587	0.00648	CbGeAlD
Carvedilol—GJA1—cardiac atrium—sarcoma	0.000579	0.00638	CbGeAlD
Carvedilol—GJA1—uterus—sarcoma	0.000576	0.00634	CbGeAlD
Carvedilol—VCAM1—lymphoid tissue—sarcoma	0.000575	0.00634	CbGeAlD
Carvedilol—HIF1A—lymphoid tissue—sarcoma	0.000553	0.0061	CbGeAlD
Carvedilol—VCAM1—tendon—sarcoma	0.00054	0.00596	CbGeAlD
Carvedilol—GJA1—lymphoid tissue—sarcoma	0.000536	0.00591	CbGeAlD
Carvedilol—VEGFA—smooth muscle tissue—sarcoma	0.00053	0.00584	CbGeAlD
Carvedilol—VCAM1—bone marrow—sarcoma	0.000523	0.00577	CbGeAlD
Carvedilol—HIF1A—tendon—sarcoma	0.00052	0.00573	CbGeAlD
Carvedilol—GJA1—tendon—sarcoma	0.000504	0.00556	CbGeAlD
Carvedilol—NDUFC2—cardiac atrium—sarcoma	0.000504	0.00555	CbGeAlD
Carvedilol—HIF1A—bone marrow—sarcoma	0.000504	0.00555	CbGeAlD
Carvedilol—NDUFC2—uterus—sarcoma	0.000501	0.00552	CbGeAlD
Carvedilol—GJA1—bone marrow—sarcoma	0.000488	0.00538	CbGeAlD
Carvedilol—SELE—testis—sarcoma	0.000486	0.00536	CbGeAlD
Carvedilol—NDUFC2—lymphoid tissue—sarcoma	0.000467	0.00515	CbGeAlD
Carvedilol—SELE—liver—sarcoma	0.00046	0.00507	CbGeAlD
Carvedilol—VEGFA—cardiac atrium—sarcoma	0.000457	0.00504	CbGeAlD
Carvedilol—VEGFA—uterus—sarcoma	0.000454	0.00501	CbGeAlD
Carvedilol—VCAM1—testis—sarcoma	0.000447	0.00493	CbGeAlD
Carvedilol—NDUFC2—tendon—sarcoma	0.000439	0.00484	CbGeAlD
Carvedilol—HIF1A—testis—sarcoma	0.00043	0.00475	CbGeAlD
Carvedilol—NDUFC2—bone marrow—sarcoma	0.000425	0.00469	CbGeAlD
Carvedilol—VCAM1—liver—sarcoma	0.000423	0.00466	CbGeAlD
Carvedilol—GJA1—testis—sarcoma	0.000418	0.0046	CbGeAlD
Carvedilol—HIF1A—liver—sarcoma	0.000407	0.00449	CbGeAlD
Carvedilol—VEGFA—tendon—sarcoma	0.000398	0.00439	CbGeAlD
Carvedilol—GJA1—liver—sarcoma	0.000395	0.00435	CbGeAlD
Carvedilol—VEGFA—bone marrow—sarcoma	0.000386	0.00425	CbGeAlD
Carvedilol—NDUFC2—testis—sarcoma	0.000363	0.00401	CbGeAlD
Carvedilol—SELE—lymph node—sarcoma	0.000353	0.00389	CbGeAlD
Carvedilol—NDUFC2—liver—sarcoma	0.000344	0.00379	CbGeAlD
Carvedilol—VEGFA—testis—sarcoma	0.00033	0.00363	CbGeAlD
Carvedilol—PTGS1—endothelium—sarcoma	0.000329	0.00363	CbGeAlD
Carvedilol—VCAM1—lymph node—sarcoma	0.000324	0.00358	CbGeAlD
Carvedilol—HIF1A—lymph node—sarcoma	0.000312	0.00344	CbGeAlD
Carvedilol—VEGFA—liver—sarcoma	0.000312	0.00344	CbGeAlD
Carvedilol—GJA1—lymph node—sarcoma	0.000303	0.00334	CbGeAlD
Carvedilol—CYP2C9—mammary gland—sarcoma	0.000291	0.00321	CbGeAlD
Carvedilol—XDH—liver—sarcoma	0.000277	0.00306	CbGeAlD
Carvedilol—ADRB1—connective tissue—sarcoma	0.000275	0.00303	CbGeAlD
Carvedilol—NDUFC2—lymph node—sarcoma	0.000263	0.0029	CbGeAlD
Carvedilol—KCNH2—myometrium—sarcoma	0.000254	0.0028	CbGeAlD
Carvedilol—ADRA2C—myometrium—sarcoma	0.000251	0.00276	CbGeAlD
Carvedilol—VEGFA—lymph node—sarcoma	0.000239	0.00263	CbGeAlD
Carvedilol—KCNH2—seminal vesicle—sarcoma	0.000229	0.00253	CbGeAlD
Carvedilol—ADRA2C—seminal vesicle—sarcoma	0.000226	0.0025	CbGeAlD
Carvedilol—ADRA1A—hematopoietic system—sarcoma	0.000226	0.00249	CbGeAlD
Carvedilol—KCNH2—hematopoietic system—sarcoma	0.000218	0.0024	CbGeAlD
Carvedilol—ADRB1—cardiac atrium—sarcoma	0.000217	0.00239	CbGeAlD
Carvedilol—ADRA2A—myometrium—sarcoma	0.0002	0.0022	CbGeAlD
Carvedilol—CYP1A2—hematopoietic system—sarcoma	0.000187	0.00206	CbGeAlD
Carvedilol—CYP1A1—hematopoietic system—sarcoma	0.000184	0.00203	CbGeAlD
Carvedilol—ADRA2A—seminal vesicle—sarcoma	0.000181	0.00199	CbGeAlD
Carvedilol—CYP2C9—hematopoietic system—sarcoma	0.000177	0.00195	CbGeAlD
Carvedilol—CYP2E1—seminal vesicle—sarcoma	0.000177	0.00195	CbGeAlD
Carvedilol—ADRA2A—hematopoietic system—sarcoma	0.000172	0.00189	CbGeAlD
Carvedilol—PTGS1—seminal vesicle—sarcoma	0.00017	0.00188	CbGeAlD
Carvedilol—CYP2E1—hematopoietic system—sarcoma	0.000168	0.00185	CbGeAlD
Carvedilol—KCNH2—cardiac atrium—sarcoma	0.000166	0.00183	CbGeAlD
Carvedilol—ADRA2A—connective tissue—sarcoma	0.000165	0.00182	CbGeAlD
Carvedilol—KCNH2—uterus—sarcoma	0.000165	0.00182	CbGeAlD
Carvedilol—ADRA2C—cardiac atrium—sarcoma	0.000163	0.0018	CbGeAlD
Carvedilol—ADRA2C—uterus—sarcoma	0.000162	0.00179	CbGeAlD
Carvedilol—PTGS1—hematopoietic system—sarcoma	0.000162	0.00178	CbGeAlD
Carvedilol—CYP1A1—skin of body—sarcoma	0.00016	0.00176	CbGeAlD
Carvedilol—ADRA1A—lymphoid tissue—sarcoma	0.000159	0.00175	CbGeAlD
Carvedilol—PTGS1—connective tissue—sarcoma	0.000156	0.00172	CbGeAlD
Carvedilol—PTGS1—smooth muscle tissue—sarcoma	0.000142	0.00157	CbGeAlD
Carvedilol—ADRA2C—tendon—sarcoma	0.000142	0.00157	CbGeAlD
Carvedilol—PTGS1—skin of body—sarcoma	0.000141	0.00155	CbGeAlD
Carvedilol—CYP1A1—cardiac atrium—sarcoma	0.00014	0.00154	CbGeAlD
Carvedilol—KCNH2—bone marrow—sarcoma	0.00014	0.00154	CbGeAlD
Carvedilol—CYP1A1—uterus—sarcoma	0.000139	0.00153	CbGeAlD
Carvedilol—CYP3A4—hematopoietic system—sarcoma	0.000135	0.00149	CbGeAlD
Carvedilol—CYP2D6—hematopoietic system—sarcoma	0.000133	0.00147	CbGeAlD
Carvedilol—ADRA2A—cardiac atrium—sarcoma	0.00013	0.00144	CbGeAlD
Carvedilol—ADRA2A—uterus—sarcoma	0.00013	0.00143	CbGeAlD
Carvedilol—PTGS1—cardiac atrium—sarcoma	0.000123	0.00135	CbGeAlD
Carvedilol—PTGS1—uterus—sarcoma	0.000122	0.00135	CbGeAlD
Carvedilol—KCNH2—testis—sarcoma	0.000119	0.00132	CbGeAlD
Carvedilol—CYP2E1—lymphoid tissue—sarcoma	0.000118	0.0013	CbGeAlD
Carvedilol—ADRA2C—testis—sarcoma	0.000118	0.0013	CbGeAlD
Carvedilol—ADRA1A—liver—sarcoma	0.000117	0.00129	CbGeAlD
Carvedilol—ADRA2A—tendon—sarcoma	0.000114	0.00125	CbGeAlD
Carvedilol—ADRA2C—liver—sarcoma	0.000111	0.00123	CbGeAlD
Carvedilol—ABCB1—myometrium—sarcoma	0.000111	0.00123	CbGeAlD
Carvedilol—CYP2E1—tendon—sarcoma	0.000111	0.00123	CbGeAlD
Carvedilol—ABCB1—embryo—sarcoma	0.000107	0.00118	CbGeAlD
Carvedilol—PTGS1—tendon—sarcoma	0.000107	0.00118	CbGeAlD
Carvedilol—Body temperature increased—Vincristine—sarcoma	0.000106	0.00105	CcSEcCtD
Carvedilol—Skin disorder—Etoposide—sarcoma	0.000105	0.00105	CcSEcCtD
Carvedilol—Hyperhidrosis—Etoposide—sarcoma	0.000105	0.00104	CcSEcCtD
Carvedilol—Orthostatic hypotension—Doxorubicin—sarcoma	0.000105	0.00104	CcSEcCtD
Carvedilol—Hypokalaemia—Doxorubicin—sarcoma	0.000104	0.00104	CcSEcCtD
Carvedilol—Angina pectoris—Epirubicin—sarcoma	0.000104	0.00104	CcSEcCtD
Carvedilol—Urticaria—Mitoxantrone—sarcoma	0.000104	0.00103	CcSEcCtD
Carvedilol—Anorexia—Etoposide—sarcoma	0.000103	0.00103	CcSEcCtD
Carvedilol—Diarrhoea—Thiotepa—sarcoma	0.000103	0.00103	CcSEcCtD
Carvedilol—Body temperature increased—Mitoxantrone—sarcoma	0.000103	0.00103	CcSEcCtD
Carvedilol—Abdominal pain—Mitoxantrone—sarcoma	0.000103	0.00103	CcSEcCtD
Carvedilol—Aspartate aminotransferase increased—Doxorubicin—sarcoma	0.000103	0.00103	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.000103	0.00103	CcSEcCtD
Carvedilol—Bronchitis—Epirubicin—sarcoma	0.000103	0.00102	CcSEcCtD
Carvedilol—Diarrhoea—Dactinomycin—sarcoma	0.000103	0.00102	CcSEcCtD
Carvedilol—Nasopharyngitis—Doxorubicin—sarcoma	0.000102	0.00102	CcSEcCtD
Carvedilol—Pancytopenia—Epirubicin—sarcoma	0.000102	0.00101	CcSEcCtD
Carvedilol—Hypotension—Etoposide—sarcoma	0.000101	0.00101	CcSEcCtD
Carvedilol—Alanine aminotransferase increased—Doxorubicin—sarcoma	0.000101	0.00101	CcSEcCtD
Carvedilol—ABCB1—seminal vesicle—sarcoma	0.000101	0.00111	CbGeAlD
Carvedilol—Dizziness—Thiotepa—sarcoma	9.99e-05	0.000994	CcSEcCtD
Carvedilol—Upper respiratory tract infection—Epirubicin—sarcoma	9.94e-05	0.000989	CcSEcCtD
Carvedilol—Influenza—Doxorubicin—sarcoma	9.9e-05	0.000985	CcSEcCtD
Carvedilol—Pollakiuria—Epirubicin—sarcoma	9.88e-05	0.000983	CcSEcCtD
Carvedilol—Hypersensitivity—Vincristine—sarcoma	9.87e-05	0.000982	CcSEcCtD
Carvedilol—Photosensitivity reaction—Epirubicin—sarcoma	9.77e-05	0.000972	CcSEcCtD
Carvedilol—Paraesthesia—Etoposide—sarcoma	9.75e-05	0.00097	CcSEcCtD
Carvedilol—Weight increased—Epirubicin—sarcoma	9.74e-05	0.000969	CcSEcCtD
Carvedilol—Weight decreased—Epirubicin—sarcoma	9.68e-05	0.000963	CcSEcCtD
Carvedilol—Dyspnoea—Etoposide—sarcoma	9.68e-05	0.000963	CcSEcCtD
Carvedilol—CYP1A2—liver—sarcoma	9.67e-05	0.00107	CbGeAlD
Carvedilol—Hyperglycaemia—Epirubicin—sarcoma	9.65e-05	0.00096	CcSEcCtD
Carvedilol—Somnolence—Etoposide—sarcoma	9.65e-05	0.00096	CcSEcCtD
Carvedilol—Angina pectoris—Doxorubicin—sarcoma	9.64e-05	0.00096	CcSEcCtD
Carvedilol—Hypersensitivity—Mitoxantrone—sarcoma	9.61e-05	0.000957	CcSEcCtD
Carvedilol—Asthenia—Vincristine—sarcoma	9.61e-05	0.000957	CcSEcCtD
Carvedilol—Vomiting—Thiotepa—sarcoma	9.61e-05	0.000956	CcSEcCtD
Carvedilol—Pneumonia—Epirubicin—sarcoma	9.6e-05	0.000955	CcSEcCtD
Carvedilol—ABCB1—hematopoietic system—sarcoma	9.56e-05	0.00105	CbGeAlD
Carvedilol—CYP1A1—liver—sarcoma	9.54e-05	0.00105	CbGeAlD
Carvedilol—Vomiting—Dactinomycin—sarcoma	9.54e-05	0.000949	CcSEcCtD
Carvedilol—Rash—Thiotepa—sarcoma	9.53e-05	0.000948	CcSEcCtD
Carvedilol—Bronchitis—Doxorubicin—sarcoma	9.52e-05	0.000947	CcSEcCtD
Carvedilol—Dermatitis—Thiotepa—sarcoma	9.52e-05	0.000947	CcSEcCtD
Carvedilol—Headache—Thiotepa—sarcoma	9.47e-05	0.000942	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Epirubicin—sarcoma	9.46e-05	0.000941	CcSEcCtD
Carvedilol—Rash—Dactinomycin—sarcoma	9.46e-05	0.000941	CcSEcCtD
Carvedilol—Decreased appetite—Etoposide—sarcoma	9.44e-05	0.000939	CcSEcCtD
Carvedilol—ADRA2A—testis—sarcoma	9.41e-05	0.00104	CbGeAlD
Carvedilol—Pancytopenia—Doxorubicin—sarcoma	9.4e-05	0.000936	CcSEcCtD
Carvedilol—Renal failure—Epirubicin—sarcoma	9.38e-05	0.000933	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Etoposide—sarcoma	9.37e-05	0.000932	CcSEcCtD
Carvedilol—Asthenia—Mitoxantrone—sarcoma	9.36e-05	0.000932	CcSEcCtD
Carvedilol—Fatigue—Etoposide—sarcoma	9.36e-05	0.000931	CcSEcCtD
Carvedilol—Constipation—Etoposide—sarcoma	9.28e-05	0.000924	CcSEcCtD
Carvedilol—Pain—Etoposide—sarcoma	9.28e-05	0.000924	CcSEcCtD
Carvedilol—Urinary tract infection—Epirubicin—sarcoma	9.27e-05	0.000923	CcSEcCtD
Carvedilol—CYP2E1—testis—sarcoma	9.2e-05	0.00101	CbGeAlD
Carvedilol—Upper respiratory tract infection—Doxorubicin—sarcoma	9.2e-05	0.000916	CcSEcCtD
Carvedilol—CYP2C9—liver—sarcoma	9.18e-05	0.00101	CbGeAlD
Carvedilol—Diarrhoea—Vincristine—sarcoma	9.17e-05	0.000912	CcSEcCtD
Carvedilol—Pollakiuria—Doxorubicin—sarcoma	9.15e-05	0.00091	CcSEcCtD
Carvedilol—Haematuria—Epirubicin—sarcoma	9.1e-05	0.000905	CcSEcCtD
Carvedilol—Photosensitivity reaction—Doxorubicin—sarcoma	9.04e-05	0.000899	CcSEcCtD
Carvedilol—Weight increased—Doxorubicin—sarcoma	9.01e-05	0.000896	CcSEcCtD
Carvedilol—Nausea—Thiotepa—sarcoma	8.98e-05	0.000893	CcSEcCtD
Carvedilol—Weight decreased—Doxorubicin—sarcoma	8.96e-05	0.000891	CcSEcCtD
Carvedilol—Sinusitis—Epirubicin—sarcoma	8.95e-05	0.000891	CcSEcCtD
Carvedilol—Feeling abnormal—Etoposide—sarcoma	8.95e-05	0.00089	CcSEcCtD
Carvedilol—Hyperglycaemia—Doxorubicin—sarcoma	8.93e-05	0.000889	CcSEcCtD
Carvedilol—Diarrhoea—Mitoxantrone—sarcoma	8.93e-05	0.000888	CcSEcCtD
Carvedilol—Nausea—Dactinomycin—sarcoma	8.91e-05	0.000886	CcSEcCtD
Carvedilol—Pneumonia—Doxorubicin—sarcoma	8.88e-05	0.000883	CcSEcCtD
Carvedilol—Gastrointestinal pain—Etoposide—sarcoma	8.88e-05	0.000883	CcSEcCtD
Carvedilol—PTGS1—testis—sarcoma	8.86e-05	0.000977	CbGeAlD
Carvedilol—Dizziness—Vincristine—sarcoma	8.86e-05	0.000882	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Doxorubicin—sarcoma	8.75e-05	0.000871	CcSEcCtD
Carvedilol—Bradycardia—Epirubicin—sarcoma	8.72e-05	0.000868	CcSEcCtD
Carvedilol—CYP2E1—liver—sarcoma	8.7e-05	0.000959	CbGeAlD
Carvedilol—Renal failure—Doxorubicin—sarcoma	8.68e-05	0.000863	CcSEcCtD
Carvedilol—KCNH2—lymph node—sarcoma	8.66e-05	0.000955	CbGeAlD
Carvedilol—Urticaria—Etoposide—sarcoma	8.62e-05	0.000858	CcSEcCtD
Carvedilol—Haemoglobin—Epirubicin—sarcoma	8.61e-05	0.000856	CcSEcCtD
Carvedilol—Rhinitis—Epirubicin—sarcoma	8.59e-05	0.000854	CcSEcCtD
Carvedilol—Body temperature increased—Etoposide—sarcoma	8.58e-05	0.000854	CcSEcCtD
Carvedilol—Abdominal pain—Etoposide—sarcoma	8.58e-05	0.000854	CcSEcCtD
Carvedilol—Urinary tract infection—Doxorubicin—sarcoma	8.58e-05	0.000854	CcSEcCtD
Carvedilol—Haemorrhage—Epirubicin—sarcoma	8.56e-05	0.000852	CcSEcCtD
Carvedilol—ADRA2C—lymph node—sarcoma	8.54e-05	0.000942	CbGeAlD
Carvedilol—Hypoaesthesia—Epirubicin—sarcoma	8.52e-05	0.000848	CcSEcCtD
Carvedilol—Vomiting—Vincristine—sarcoma	8.52e-05	0.000848	CcSEcCtD
Carvedilol—Pharyngitis—Epirubicin—sarcoma	8.5e-05	0.000846	CcSEcCtD
Carvedilol—Urinary tract disorder—Epirubicin—sarcoma	8.46e-05	0.000842	CcSEcCtD
Carvedilol—Rash—Vincristine—sarcoma	8.45e-05	0.000841	CcSEcCtD
Carvedilol—Dermatitis—Vincristine—sarcoma	8.44e-05	0.00084	CcSEcCtD
Carvedilol—Oedema peripheral—Epirubicin—sarcoma	8.44e-05	0.000839	CcSEcCtD
Carvedilol—Haematuria—Doxorubicin—sarcoma	8.42e-05	0.000837	CcSEcCtD
Carvedilol—Urethral disorder—Epirubicin—sarcoma	8.4e-05	0.000835	CcSEcCtD
Carvedilol—Headache—Vincristine—sarcoma	8.39e-05	0.000835	CcSEcCtD
Carvedilol—Vomiting—Mitoxantrone—sarcoma	8.3e-05	0.000826	CcSEcCtD
Carvedilol—Sinusitis—Doxorubicin—sarcoma	8.28e-05	0.000824	CcSEcCtD
Carvedilol—Visual impairment—Epirubicin—sarcoma	8.25e-05	0.000821	CcSEcCtD
Carvedilol—Rash—Mitoxantrone—sarcoma	8.23e-05	0.000819	CcSEcCtD
Carvedilol—Dermatitis—Mitoxantrone—sarcoma	8.22e-05	0.000818	CcSEcCtD
Carvedilol—Headache—Mitoxantrone—sarcoma	8.18e-05	0.000813	CcSEcCtD
Carvedilol—Erythema multiforme—Epirubicin—sarcoma	8.1e-05	0.000806	CcSEcCtD
Carvedilol—Bradycardia—Doxorubicin—sarcoma	8.07e-05	0.000803	CcSEcCtD
Carvedilol—Hypersensitivity—Etoposide—sarcoma	8e-05	0.000796	CcSEcCtD
Carvedilol—Tinnitus—Epirubicin—sarcoma	7.99e-05	0.000795	CcSEcCtD
Carvedilol—Haemoglobin—Doxorubicin—sarcoma	7.96e-05	0.000792	CcSEcCtD
Carvedilol—Nausea—Vincristine—sarcoma	7.96e-05	0.000792	CcSEcCtD
Carvedilol—Rhinitis—Doxorubicin—sarcoma	7.94e-05	0.00079	CcSEcCtD
Carvedilol—Haemorrhage—Doxorubicin—sarcoma	7.92e-05	0.000788	CcSEcCtD
Carvedilol—Hypoaesthesia—Doxorubicin—sarcoma	7.88e-05	0.000785	CcSEcCtD
Carvedilol—Pharyngitis—Doxorubicin—sarcoma	7.87e-05	0.000783	CcSEcCtD
Carvedilol—Urinary tract disorder—Doxorubicin—sarcoma	7.83e-05	0.000779	CcSEcCtD
Carvedilol—Oedema peripheral—Doxorubicin—sarcoma	7.81e-05	0.000777	CcSEcCtD
Carvedilol—Asthenia—Etoposide—sarcoma	7.79e-05	0.000775	CcSEcCtD
Carvedilol—Angiopathy—Epirubicin—sarcoma	7.77e-05	0.000773	CcSEcCtD
Carvedilol—Urethral disorder—Doxorubicin—sarcoma	7.77e-05	0.000773	CcSEcCtD
Carvedilol—Nausea—Mitoxantrone—sarcoma	7.75e-05	0.000771	CcSEcCtD
Carvedilol—Immune system disorder—Epirubicin—sarcoma	7.74e-05	0.00077	CcSEcCtD
Carvedilol—Mediastinal disorder—Epirubicin—sarcoma	7.72e-05	0.000768	CcSEcCtD
Carvedilol—Pruritus—Etoposide—sarcoma	7.68e-05	0.000764	CcSEcCtD
Carvedilol—Visual impairment—Doxorubicin—sarcoma	7.64e-05	0.00076	CcSEcCtD
Carvedilol—Alopecia—Epirubicin—sarcoma	7.57e-05	0.000753	CcSEcCtD
Carvedilol—Erythema multiforme—Doxorubicin—sarcoma	7.49e-05	0.000746	CcSEcCtD
Carvedilol—Malnutrition—Epirubicin—sarcoma	7.46e-05	0.000742	CcSEcCtD
Carvedilol—Diarrhoea—Etoposide—sarcoma	7.43e-05	0.000739	CcSEcCtD
Carvedilol—Tinnitus—Doxorubicin—sarcoma	7.39e-05	0.000735	CcSEcCtD
Carvedilol—Flatulence—Epirubicin—sarcoma	7.35e-05	0.000731	CcSEcCtD
Carvedilol—Tension—Epirubicin—sarcoma	7.32e-05	0.000728	CcSEcCtD
Carvedilol—CYP1A1—lymph node—sarcoma	7.31e-05	0.000806	CbGeAlD
Carvedilol—CYP2D6—testis—sarcoma	7.29e-05	0.000803	CbGeAlD
Carvedilol—Nervousness—Epirubicin—sarcoma	7.24e-05	0.00072	CcSEcCtD
Carvedilol—ABCB1—uterus—sarcoma	7.22e-05	0.000796	CbGeAlD
Carvedilol—Back pain—Epirubicin—sarcoma	7.21e-05	0.000718	CcSEcCtD
Carvedilol—Angiopathy—Doxorubicin—sarcoma	7.19e-05	0.000715	CcSEcCtD
Carvedilol—Dizziness—Etoposide—sarcoma	7.18e-05	0.000714	CcSEcCtD
Carvedilol—Muscle spasms—Epirubicin—sarcoma	7.17e-05	0.000713	CcSEcCtD
Carvedilol—Immune system disorder—Doxorubicin—sarcoma	7.16e-05	0.000712	CcSEcCtD
Carvedilol—Mediastinal disorder—Doxorubicin—sarcoma	7.14e-05	0.000711	CcSEcCtD
Carvedilol—Vision blurred—Epirubicin—sarcoma	7.03e-05	0.000699	CcSEcCtD
Carvedilol—Alopecia—Doxorubicin—sarcoma	7e-05	0.000697	CcSEcCtD
Carvedilol—CYP3A4—liver—sarcoma	7e-05	0.000772	CbGeAlD
Carvedilol—Ill-defined disorder—Epirubicin—sarcoma	6.92e-05	0.000688	CcSEcCtD
Carvedilol—Vomiting—Etoposide—sarcoma	6.9e-05	0.000687	CcSEcCtD
Carvedilol—Malnutrition—Doxorubicin—sarcoma	6.9e-05	0.000686	CcSEcCtD
Carvedilol—Anaemia—Epirubicin—sarcoma	6.89e-05	0.000686	CcSEcCtD
Carvedilol—CYP2D6—liver—sarcoma	6.89e-05	0.000759	CbGeAlD
Carvedilol—Rash—Etoposide—sarcoma	6.84e-05	0.000681	CcSEcCtD
Carvedilol—Dermatitis—Etoposide—sarcoma	6.84e-05	0.00068	CcSEcCtD
Carvedilol—ADRA2A—lymph node—sarcoma	6.82e-05	0.000752	CbGeAlD
Carvedilol—Headache—Etoposide—sarcoma	6.8e-05	0.000677	CcSEcCtD
Carvedilol—Flatulence—Doxorubicin—sarcoma	6.8e-05	0.000676	CcSEcCtD
Carvedilol—Tension—Doxorubicin—sarcoma	6.77e-05	0.000674	CcSEcCtD
Carvedilol—ABCB1—lymphoid tissue—sarcoma	6.73e-05	0.000742	CbGeAlD
Carvedilol—Malaise—Epirubicin—sarcoma	6.72e-05	0.000669	CcSEcCtD
Carvedilol—Nervousness—Doxorubicin—sarcoma	6.7e-05	0.000667	CcSEcCtD
Carvedilol—Vertigo—Epirubicin—sarcoma	6.7e-05	0.000666	CcSEcCtD
Carvedilol—Syncope—Epirubicin—sarcoma	6.69e-05	0.000665	CcSEcCtD
Carvedilol—Leukopenia—Epirubicin—sarcoma	6.67e-05	0.000664	CcSEcCtD
Carvedilol—Back pain—Doxorubicin—sarcoma	6.67e-05	0.000664	CcSEcCtD
Carvedilol—Muscle spasms—Doxorubicin—sarcoma	6.63e-05	0.00066	CcSEcCtD
Carvedilol—Palpitations—Epirubicin—sarcoma	6.59e-05	0.000656	CcSEcCtD
Carvedilol—Loss of consciousness—Epirubicin—sarcoma	6.55e-05	0.000652	CcSEcCtD
Carvedilol—Cough—Epirubicin—sarcoma	6.51e-05	0.000647	CcSEcCtD
Carvedilol—Vision blurred—Doxorubicin—sarcoma	6.5e-05	0.000647	CcSEcCtD
Carvedilol—Convulsion—Epirubicin—sarcoma	6.46e-05	0.000643	CcSEcCtD
Carvedilol—Nausea—Etoposide—sarcoma	6.45e-05	0.000642	CcSEcCtD
Carvedilol—Hypertension—Epirubicin—sarcoma	6.44e-05	0.00064	CcSEcCtD
Carvedilol—PTGS1—lymph node—sarcoma	6.43e-05	0.000708	CbGeAlD
Carvedilol—Ill-defined disorder—Doxorubicin—sarcoma	6.4e-05	0.000637	CcSEcCtD
Carvedilol—Anaemia—Doxorubicin—sarcoma	6.38e-05	0.000634	CcSEcCtD
Carvedilol—Myalgia—Epirubicin—sarcoma	6.35e-05	0.000632	CcSEcCtD
Carvedilol—Arthralgia—Epirubicin—sarcoma	6.35e-05	0.000632	CcSEcCtD
Carvedilol—Chest pain—Epirubicin—sarcoma	6.35e-05	0.000632	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	6.3e-05	0.000627	CcSEcCtD
Carvedilol—Discomfort—Epirubicin—sarcoma	6.27e-05	0.000624	CcSEcCtD
Carvedilol—Malaise—Doxorubicin—sarcoma	6.22e-05	0.000619	CcSEcCtD
Carvedilol—Dry mouth—Epirubicin—sarcoma	6.21e-05	0.000618	CcSEcCtD
Carvedilol—Vertigo—Doxorubicin—sarcoma	6.2e-05	0.000617	CcSEcCtD
Carvedilol—Syncope—Doxorubicin—sarcoma	6.19e-05	0.000616	CcSEcCtD
Carvedilol—Leukopenia—Doxorubicin—sarcoma	6.18e-05	0.000614	CcSEcCtD
Carvedilol—Confusional state—Epirubicin—sarcoma	6.14e-05	0.00061	CcSEcCtD
Carvedilol—ABCB1—bone marrow—sarcoma	6.13e-05	0.000676	CbGeAlD
Carvedilol—Palpitations—Doxorubicin—sarcoma	6.1e-05	0.000607	CcSEcCtD
Carvedilol—Oedema—Epirubicin—sarcoma	6.08e-05	0.000605	CcSEcCtD
Carvedilol—Anaphylactic shock—Epirubicin—sarcoma	6.08e-05	0.000605	CcSEcCtD
Carvedilol—Loss of consciousness—Doxorubicin—sarcoma	6.06e-05	0.000603	CcSEcCtD
Carvedilol—Infection—Epirubicin—sarcoma	6.05e-05	0.000601	CcSEcCtD
Carvedilol—Cough—Doxorubicin—sarcoma	6.02e-05	0.000599	CcSEcCtD
Carvedilol—Shock—Epirubicin—sarcoma	5.99e-05	0.000596	CcSEcCtD
Carvedilol—Convulsion—Doxorubicin—sarcoma	5.98e-05	0.000595	CcSEcCtD
Carvedilol—Thrombocytopenia—Epirubicin—sarcoma	5.96e-05	0.000593	CcSEcCtD
Carvedilol—Hypertension—Doxorubicin—sarcoma	5.96e-05	0.000593	CcSEcCtD
Carvedilol—Tachycardia—Epirubicin—sarcoma	5.94e-05	0.000591	CcSEcCtD
Carvedilol—Skin disorder—Epirubicin—sarcoma	5.91e-05	0.000588	CcSEcCtD
Carvedilol—Hyperhidrosis—Epirubicin—sarcoma	5.88e-05	0.000585	CcSEcCtD
Carvedilol—Chest pain—Doxorubicin—sarcoma	5.87e-05	0.000584	CcSEcCtD
Carvedilol—Arthralgia—Doxorubicin—sarcoma	5.87e-05	0.000584	CcSEcCtD
Carvedilol—Myalgia—Doxorubicin—sarcoma	5.87e-05	0.000584	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	5.83e-05	0.00058	CcSEcCtD
Carvedilol—Discomfort—Doxorubicin—sarcoma	5.8e-05	0.000577	CcSEcCtD
Carvedilol—Anorexia—Epirubicin—sarcoma	5.8e-05	0.000577	CcSEcCtD
Carvedilol—Dry mouth—Doxorubicin—sarcoma	5.74e-05	0.000572	CcSEcCtD
Carvedilol—Hypotension—Epirubicin—sarcoma	5.69e-05	0.000566	CcSEcCtD
Carvedilol—Confusional state—Doxorubicin—sarcoma	5.68e-05	0.000565	CcSEcCtD
Carvedilol—Anaphylactic shock—Doxorubicin—sarcoma	5.63e-05	0.00056	CcSEcCtD
Carvedilol—Oedema—Doxorubicin—sarcoma	5.63e-05	0.00056	CcSEcCtD
Carvedilol—Infection—Doxorubicin—sarcoma	5.59e-05	0.000557	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Epirubicin—sarcoma	5.54e-05	0.000552	CcSEcCtD
Carvedilol—Shock—Doxorubicin—sarcoma	5.54e-05	0.000551	CcSEcCtD
Carvedilol—Thrombocytopenia—Doxorubicin—sarcoma	5.51e-05	0.000548	CcSEcCtD
Carvedilol—Insomnia—Epirubicin—sarcoma	5.5e-05	0.000548	CcSEcCtD
Carvedilol—Tachycardia—Doxorubicin—sarcoma	5.49e-05	0.000547	CcSEcCtD
Carvedilol—Skin disorder—Doxorubicin—sarcoma	5.47e-05	0.000544	CcSEcCtD
Carvedilol—Paraesthesia—Epirubicin—sarcoma	5.46e-05	0.000544	CcSEcCtD
Carvedilol—Hyperhidrosis—Doxorubicin—sarcoma	5.44e-05	0.000542	CcSEcCtD
Carvedilol—Dyspnoea—Epirubicin—sarcoma	5.42e-05	0.00054	CcSEcCtD
Carvedilol—Somnolence—Epirubicin—sarcoma	5.41e-05	0.000538	CcSEcCtD
Carvedilol—Anorexia—Doxorubicin—sarcoma	5.37e-05	0.000534	CcSEcCtD
Carvedilol—Dyspepsia—Epirubicin—sarcoma	5.36e-05	0.000533	CcSEcCtD
Carvedilol—Decreased appetite—Epirubicin—sarcoma	5.29e-05	0.000526	CcSEcCtD
Carvedilol—Hypotension—Doxorubicin—sarcoma	5.26e-05	0.000523	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Epirubicin—sarcoma	5.25e-05	0.000523	CcSEcCtD
Carvedilol—Fatigue—Epirubicin—sarcoma	5.25e-05	0.000522	CcSEcCtD
Carvedilol—ABCB1—testis—sarcoma	5.24e-05	0.000578	CbGeAlD
Carvedilol—Pain—Epirubicin—sarcoma	5.2e-05	0.000518	CcSEcCtD
Carvedilol—Constipation—Epirubicin—sarcoma	5.2e-05	0.000518	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Doxorubicin—sarcoma	5.13e-05	0.00051	CcSEcCtD
Carvedilol—Insomnia—Doxorubicin—sarcoma	5.09e-05	0.000507	CcSEcCtD
Carvedilol—Paraesthesia—Doxorubicin—sarcoma	5.06e-05	0.000503	CcSEcCtD
Carvedilol—Dyspnoea—Doxorubicin—sarcoma	5.02e-05	0.000499	CcSEcCtD
Carvedilol—Feeling abnormal—Epirubicin—sarcoma	5.01e-05	0.000499	CcSEcCtD
Carvedilol—Somnolence—Doxorubicin—sarcoma	5.01e-05	0.000498	CcSEcCtD
Carvedilol—Gastrointestinal pain—Epirubicin—sarcoma	4.98e-05	0.000495	CcSEcCtD
Carvedilol—Dyspepsia—Doxorubicin—sarcoma	4.96e-05	0.000493	CcSEcCtD
Carvedilol—ABCB1—liver—sarcoma	4.96e-05	0.000546	CbGeAlD
Carvedilol—Decreased appetite—Doxorubicin—sarcoma	4.89e-05	0.000487	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Doxorubicin—sarcoma	4.86e-05	0.000484	CcSEcCtD
Carvedilol—Fatigue—Doxorubicin—sarcoma	4.85e-05	0.000483	CcSEcCtD
Carvedilol—Urticaria—Epirubicin—sarcoma	4.83e-05	0.000481	CcSEcCtD
Carvedilol—Constipation—Doxorubicin—sarcoma	4.81e-05	0.000479	CcSEcCtD
Carvedilol—Pain—Doxorubicin—sarcoma	4.81e-05	0.000479	CcSEcCtD
Carvedilol—Abdominal pain—Epirubicin—sarcoma	4.81e-05	0.000479	CcSEcCtD
Carvedilol—Body temperature increased—Epirubicin—sarcoma	4.81e-05	0.000479	CcSEcCtD
Carvedilol—Feeling abnormal—Doxorubicin—sarcoma	4.64e-05	0.000462	CcSEcCtD
Carvedilol—Gastrointestinal pain—Doxorubicin—sarcoma	4.6e-05	0.000458	CcSEcCtD
Carvedilol—Hypersensitivity—Epirubicin—sarcoma	4.48e-05	0.000446	CcSEcCtD
Carvedilol—Urticaria—Doxorubicin—sarcoma	4.47e-05	0.000445	CcSEcCtD
Carvedilol—Abdominal pain—Doxorubicin—sarcoma	4.45e-05	0.000443	CcSEcCtD
Carvedilol—Body temperature increased—Doxorubicin—sarcoma	4.45e-05	0.000443	CcSEcCtD
Carvedilol—Asthenia—Epirubicin—sarcoma	4.37e-05	0.000434	CcSEcCtD
Carvedilol—Pruritus—Epirubicin—sarcoma	4.31e-05	0.000428	CcSEcCtD
Carvedilol—Diarrhoea—Epirubicin—sarcoma	4.16e-05	0.000414	CcSEcCtD
Carvedilol—Hypersensitivity—Doxorubicin—sarcoma	4.15e-05	0.000413	CcSEcCtD
Carvedilol—Asthenia—Doxorubicin—sarcoma	4.04e-05	0.000402	CcSEcCtD
Carvedilol—Dizziness—Epirubicin—sarcoma	4.02e-05	0.0004	CcSEcCtD
Carvedilol—Pruritus—Doxorubicin—sarcoma	3.98e-05	0.000396	CcSEcCtD
Carvedilol—Vomiting—Epirubicin—sarcoma	3.87e-05	0.000385	CcSEcCtD
Carvedilol—Diarrhoea—Doxorubicin—sarcoma	3.85e-05	0.000383	CcSEcCtD
Carvedilol—Rash—Epirubicin—sarcoma	3.84e-05	0.000382	CcSEcCtD
Carvedilol—Dermatitis—Epirubicin—sarcoma	3.83e-05	0.000381	CcSEcCtD
Carvedilol—Headache—Epirubicin—sarcoma	3.81e-05	0.000379	CcSEcCtD
Carvedilol—ABCB1—lymph node—sarcoma	3.8e-05	0.000419	CbGeAlD
Carvedilol—Dizziness—Doxorubicin—sarcoma	3.72e-05	0.00037	CcSEcCtD
Carvedilol—Nausea—Epirubicin—sarcoma	3.61e-05	0.00036	CcSEcCtD
Carvedilol—Vomiting—Doxorubicin—sarcoma	3.58e-05	0.000356	CcSEcCtD
Carvedilol—Rash—Doxorubicin—sarcoma	3.55e-05	0.000353	CcSEcCtD
Carvedilol—Dermatitis—Doxorubicin—sarcoma	3.55e-05	0.000353	CcSEcCtD
Carvedilol—Headache—Doxorubicin—sarcoma	3.53e-05	0.000351	CcSEcCtD
Carvedilol—Nausea—Doxorubicin—sarcoma	3.34e-05	0.000333	CcSEcCtD
Carvedilol—ADRA2A—Hemostasis—VEGFA—sarcoma	6.04e-06	4.83e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MDM2—sarcoma	6.03e-06	4.83e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ATF1—sarcoma	6.02e-06	4.81e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—TP53—sarcoma	6.01e-06	4.81e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—FOXO1—sarcoma	5.98e-06	4.78e-05	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—IL2—sarcoma	5.97e-06	4.78e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PDGFRB—sarcoma	5.97e-06	4.77e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—NRAS—sarcoma	5.97e-06	4.77e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—IL2—sarcoma	5.95e-06	4.76e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—CREB1—sarcoma	5.94e-06	4.75e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—FOXO1—sarcoma	5.92e-06	4.74e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—IL2—sarcoma	5.92e-06	4.74e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PDGFRB—sarcoma	5.91e-06	4.73e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PDGFRA—sarcoma	5.87e-06	4.7e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—FOXO1—sarcoma	5.85e-06	4.68e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—IL2—sarcoma	5.84e-06	4.68e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PDGFRB—sarcoma	5.84e-06	4.67e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PDGFRA—sarcoma	5.82e-06	4.66e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ENO2—sarcoma	5.82e-06	4.65e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IGF1R—sarcoma	5.81e-06	4.65e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—HBA1—sarcoma	5.78e-06	4.63e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ENO2—sarcoma	5.77e-06	4.61e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—HRAS—sarcoma	5.75e-06	4.6e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PDGFRA—sarcoma	5.75e-06	4.6e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—HBA1—sarcoma	5.73e-06	4.59e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IGF1R—sarcoma	5.72e-06	4.58e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—TP53—sarcoma	5.62e-06	4.5e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—HRAS—sarcoma	5.61e-06	4.49e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—FOXO1—sarcoma	5.53e-06	4.43e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—IL2—sarcoma	5.53e-06	4.43e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PDGFRB—sarcoma	5.52e-06	4.42e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CREB1—sarcoma	5.52e-06	4.42e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—FOXO1—sarcoma	5.44e-06	4.36e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—IL2—sarcoma	5.44e-06	4.36e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PDGFRA—sarcoma	5.44e-06	4.35e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PDGFRB—sarcoma	5.43e-06	4.35e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KDR—sarcoma	5.43e-06	4.34e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—IL2—sarcoma	5.42e-06	4.34e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IL2—sarcoma	5.4e-06	4.32e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IL2—sarcoma	5.39e-06	4.31e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—IL2—sarcoma	5.38e-06	4.3e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—HRAS—sarcoma	5.37e-06	4.3e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PDGFRA—sarcoma	5.35e-06	4.28e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—IL2—sarcoma	5.31e-06	4.25e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CCND1—sarcoma	5.26e-06	4.21e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—JUN—sarcoma	5.25e-06	4.2e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CCND1—sarcoma	5.25e-06	4.2e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—JUN—sarcoma	5.24e-06	4.19e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PLCG1—sarcoma	5.24e-06	4.19e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CTNNB1—sarcoma	5.21e-06	4.17e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CTNNB1—sarcoma	5.2e-06	4.16e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—KRAS—sarcoma	5.13e-06	4.11e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IGF1R—sarcoma	5.08e-06	4.07e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL2—sarcoma	5.02e-06	4.02e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KIT—sarcoma	5e-06	4e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—NRAS—sarcoma	5e-06	4e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KDR—sarcoma	4.94e-06	3.96e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL2—sarcoma	4.94e-06	3.95e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PLCG1—sarcoma	4.93e-06	3.95e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ENO2—sarcoma	4.93e-06	3.94e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KDR—sarcoma	4.9e-06	3.92e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—HBA1—sarcoma	4.9e-06	3.92e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PLCG1—sarcoma	4.89e-06	3.92e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KDR—sarcoma	4.84e-06	3.87e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—FOXO1—sarcoma	4.84e-06	3.87e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—IL2—sarcoma	4.83e-06	3.87e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PDGFRB—sarcoma	4.83e-06	3.86e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CREB1—sarcoma	4.76e-06	3.81e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PDGFRA—sarcoma	4.75e-06	3.8e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IGF1R—sarcoma	4.72e-06	3.78e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—SRC—sarcoma	4.71e-06	3.77e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—SRC—sarcoma	4.7e-06	3.76e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—VEGFA—sarcoma	4.59e-06	3.67e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KDR—sarcoma	4.58e-06	3.66e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TP53—sarcoma	4.56e-06	3.65e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KIT—sarcoma	4.55e-06	3.64e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—NRAS—sarcoma	4.55e-06	3.64e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—EGFR—sarcoma	4.55e-06	3.64e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—NRAS—sarcoma	4.53e-06	3.63e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—NRAS—sarcoma	4.52e-06	3.62e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KIT—sarcoma	4.51e-06	3.61e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—NRAS—sarcoma	4.51e-06	3.61e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KDR—sarcoma	4.5e-06	3.6e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—FOXO1—sarcoma	4.49e-06	3.6e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—IL2—sarcoma	4.49e-06	3.59e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PDGFRB—sarcoma	4.49e-06	3.59e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KIT—sarcoma	4.45e-06	3.57e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—NRAS—sarcoma	4.45e-06	3.57e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PDGFRA—sarcoma	4.42e-06	3.53e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL2—sarcoma	4.39e-06	3.51e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—HRAS—sarcoma	4.36e-06	3.49e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CREB1—sarcoma	4.33e-06	3.47e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—KRAS—sarcoma	4.3e-06	3.44e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CREB1—sarcoma	4.3e-06	3.44e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CREB1—sarcoma	4.24e-06	3.39e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MYC—sarcoma	4.22e-06	3.38e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KIT—sarcoma	4.21e-06	3.37e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—NRAS—sarcoma	4.21e-06	3.37e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MYC—sarcoma	4.21e-06	3.37e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PLCG1—sarcoma	4.18e-06	3.35e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—EGFR—sarcoma	4.15e-06	3.32e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KIT—sarcoma	4.15e-06	3.32e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—NRAS—sarcoma	4.15e-06	3.32e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—EGFR—sarcoma	4.13e-06	3.3e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—EGFR—sarcoma	4.12e-06	3.3e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—EGFR—sarcoma	4.11e-06	3.29e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL2—sarcoma	4.08e-06	3.26e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—EGFR—sarcoma	4.06e-06	3.25e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CREB1—sarcoma	4.01e-06	3.21e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KDR—sarcoma	4e-06	3.2e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CREB1—sarcoma	3.95e-06	3.16e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MDM2—sarcoma	3.94e-06	3.15e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—KRAS—sarcoma	3.92e-06	3.14e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—KRAS—sarcoma	3.9e-06	3.12e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—KRAS—sarcoma	3.89e-06	3.12e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—KRAS—sarcoma	3.88e-06	3.11e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—EGFR—sarcoma	3.84e-06	3.07e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—KRAS—sarcoma	3.83e-06	3.07e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ENO2—sarcoma	3.8e-06	3.04e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—EGFR—sarcoma	3.78e-06	3.02e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—HBA1—sarcoma	3.78e-06	3.02e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KDR—sarcoma	3.72e-06	2.97e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KIT—sarcoma	3.68e-06	2.95e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—NRAS—sarcoma	3.68e-06	2.95e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—HRAS—sarcoma	3.66e-06	2.93e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—KRAS—sarcoma	3.63e-06	2.9e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MDM2—sarcoma	3.59e-06	2.87e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—KRAS—sarcoma	3.57e-06	2.86e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MDM2—sarcoma	3.55e-06	2.84e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL2—sarcoma	3.52e-06	2.81e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MDM2—sarcoma	3.51e-06	2.81e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CREB1—sarcoma	3.51e-06	2.81e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—sarcoma	3.47e-06	2.77e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—sarcoma	3.46e-06	2.77e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CCND1—sarcoma	3.43e-06	2.74e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KIT—sarcoma	3.42e-06	2.74e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—NRAS—sarcoma	3.42e-06	2.74e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—JUN—sarcoma	3.42e-06	2.74e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CTNNB1—sarcoma	3.4e-06	2.72e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—EGFR—sarcoma	3.36e-06	2.69e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—HRAS—sarcoma	3.33e-06	2.67e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MDM2—sarcoma	3.32e-06	2.66e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—HRAS—sarcoma	3.32e-06	2.65e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—HRAS—sarcoma	3.31e-06	2.65e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—HRAS—sarcoma	3.3e-06	2.64e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MDM2—sarcoma	3.27e-06	2.61e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—HRAS—sarcoma	3.26e-06	2.61e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CREB1—sarcoma	3.26e-06	2.61e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PLCG1—sarcoma	3.23e-06	2.58e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL2—sarcoma	3.2e-06	2.56e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL2—sarcoma	3.18e-06	2.54e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—KRAS—sarcoma	3.17e-06	2.54e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL2—sarcoma	3.13e-06	2.51e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCND1—sarcoma	3.12e-06	2.5e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—EGFR—sarcoma	3.12e-06	2.5e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—JUN—sarcoma	3.12e-06	2.49e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCND1—sarcoma	3.1e-06	2.48e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CTNNB1—sarcoma	3.09e-06	2.48e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—JUN—sarcoma	3.09e-06	2.47e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—HRAS—sarcoma	3.08e-06	2.47e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—SRC—sarcoma	3.07e-06	2.46e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CTNNB1—sarcoma	3.07e-06	2.45e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCND1—sarcoma	3.06e-06	2.45e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—JUN—sarcoma	3.05e-06	2.44e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—HRAS—sarcoma	3.03e-06	2.43e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CTNNB1—sarcoma	3.03e-06	2.42e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—VEGFA—sarcoma	2.99e-06	2.39e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL2—sarcoma	2.97e-06	2.37e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NRAS—sarcoma	2.95e-06	2.36e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—KRAS—sarcoma	2.95e-06	2.36e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL2—sarcoma	2.92e-06	2.34e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MDM2—sarcoma	2.9e-06	2.32e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCND1—sarcoma	2.89e-06	2.31e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—JUN—sarcoma	2.89e-06	2.31e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CTNNB1—sarcoma	2.86e-06	2.29e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCND1—sarcoma	2.85e-06	2.28e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—JUN—sarcoma	2.84e-06	2.27e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CTNNB1—sarcoma	2.82e-06	2.26e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—SRC—sarcoma	2.8e-06	2.24e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—SRC—sarcoma	2.77e-06	2.22e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MYC—sarcoma	2.75e-06	2.2e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—SRC—sarcoma	2.74e-06	2.19e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—VEGFA—sarcoma	2.72e-06	2.18e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—VEGFA—sarcoma	2.7e-06	2.16e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MDM2—sarcoma	2.7e-06	2.16e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—HRAS—sarcoma	2.7e-06	2.16e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NRAS—sarcoma	2.69e-06	2.15e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EGFR—sarcoma	2.69e-06	2.15e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NRAS—sarcoma	2.67e-06	2.13e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—VEGFA—sarcoma	2.66e-06	2.13e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NRAS—sarcoma	2.63e-06	2.11e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL2—sarcoma	2.59e-06	2.08e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—SRC—sarcoma	2.59e-06	2.07e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—SRC—sarcoma	2.55e-06	2.04e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KRAS—sarcoma	2.54e-06	2.03e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCND1—sarcoma	2.53e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—JUN—sarcoma	2.52e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—VEGFA—sarcoma	2.52e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MYC—sarcoma	2.51e-06	2.01e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—HRAS—sarcoma	2.5e-06	2e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CTNNB1—sarcoma	2.5e-06	2e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NRAS—sarcoma	2.49e-06	1.99e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MYC—sarcoma	2.48e-06	1.99e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—VEGFA—sarcoma	2.48e-06	1.99e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MYC—sarcoma	2.45e-06	1.96e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EGFR—sarcoma	2.45e-06	1.96e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NRAS—sarcoma	2.45e-06	1.96e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EGFR—sarcoma	2.43e-06	1.94e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL2—sarcoma	2.41e-06	1.93e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EGFR—sarcoma	2.4e-06	1.92e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCND1—sarcoma	2.35e-06	1.88e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—JUN—sarcoma	2.34e-06	1.88e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CTNNB1—sarcoma	2.33e-06	1.86e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MYC—sarcoma	2.32e-06	1.86e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KRAS—sarcoma	2.32e-06	1.85e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KRAS—sarcoma	2.29e-06	1.84e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MYC—sarcoma	2.28e-06	1.83e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EGFR—sarcoma	2.27e-06	1.82e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KRAS—sarcoma	2.26e-06	1.81e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SRC—sarcoma	2.26e-06	1.81e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—sarcoma	2.26e-06	1.81e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EGFR—sarcoma	2.23e-06	1.79e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—VEGFA—sarcoma	2.2e-06	1.76e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NRAS—sarcoma	2.18e-06	1.74e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HRAS—sarcoma	2.16e-06	1.73e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KRAS—sarcoma	2.14e-06	1.72e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KRAS—sarcoma	2.11e-06	1.69e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SRC—sarcoma	2.1e-06	1.68e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—sarcoma	2.06e-06	1.65e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—VEGFA—sarcoma	2.05e-06	1.64e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—sarcoma	2.04e-06	1.63e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MYC—sarcoma	2.03e-06	1.62e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NRAS—sarcoma	2.02e-06	1.62e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—sarcoma	2.01e-06	1.61e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EGFR—sarcoma	1.98e-06	1.59e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HRAS—sarcoma	1.97e-06	1.58e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HRAS—sarcoma	1.95e-06	1.56e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HRAS—sarcoma	1.93e-06	1.54e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—sarcoma	1.9e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MYC—sarcoma	1.88e-06	1.51e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—sarcoma	1.87e-06	1.5e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KRAS—sarcoma	1.87e-06	1.5e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGFR—sarcoma	1.84e-06	1.47e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HRAS—sarcoma	1.82e-06	1.46e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HRAS—sarcoma	1.79e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KRAS—sarcoma	1.74e-06	1.39e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—sarcoma	1.67e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HRAS—sarcoma	1.59e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—sarcoma	1.55e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HRAS—sarcoma	1.48e-06	1.18e-05	CbGpPWpGaD
